T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR

Exclusion Criteria

• •1.Ann Arbor Stage I disease. 2.History of any other malignancy within the past 5 years, except for locally curable malignancies that have been treated with curative intent (e.g., basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast).
• •3.Active infection, including:
• •1. Known active or latent tuberculosis, evidenced by a positive tuberculin (PPD) skin test (where a positive result is defined as an induration \>10 mm or per local clinical standards) or findings suggestive of active/latent TB on chest X-ray/CT.
• •2. Known history of Human Immunodeficiency Virus (HIV) infection and/or AIDS.
• •3. Chronic active hepatitis B or C infection:
• •1. For hepatitis B virus (HBV): Subjects who are HBV DNA positive are excluded. Subjects with undetectable HBV DNA levels are eligible. The upper limit of normal (ULN) for HBV DNA is determined by the local laboratory at each center.
• •2. For hepatitis C virus (HCV): Subjects who are HCV RNA positive are excluded. Subjects with undetectable HCV RNA are eligible. The ULN for HCV RNA is determined by the local laboratory at each center.
• •4. Active viral infections other than hepatitis B or C (e.g., herpes zoster), or cytomegalovirus (CMV) infection.
• •5. Infection requiring intravenous antimicrobial therapy: evidenced by infection-related hemodynamic instability, worsening or new-onset infectious symptoms/signs, radiologic evidence of a new infectious focus, or persistent fever without localizing signs where infection cannot be ruled out.
• •6. Positive serological test for Epstein-Barr virus (EBV). 4.Poorly controlled cardiac symptoms or diseases, such as: i. Heart failure \> New York Heart Association (NYHA) Class II. ii. Unstable angina. iii. Myocardial infarction within the past year. iv. Clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention.
• •5.Pregnant or lactating women, and subjects of childbearing potential unwilling to employ effective contraception.
• •6.Patients with psychiatric disorders or those unable to provide informed consent.
• •7.Any other condition which, in the investigator's judgment, makes the subject unsuitable for participation in this study